Compare Heron Therapeutics Inc (HRTX) vs Twilio Inc (TWLO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Twilio Inc — how do they compare? Heron Therapeutics Inc trades at $0.37 (market cap $74.04M), while Twilio Inc trades at $276.61 (market cap $41.93B). The key difference: Twilio Inc is far larger — about 566.3× Heron Therapeutics Inc's market cap, and Twilio Inc is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and Twilio Inc for 56 Days on average.
| HRTX | TWLO | |
|---|---|---|
Market Cap | $74.04M | $41.93B |
Volume | 3,668,095 | 3,480,421 |
Sector | Health | Technology |
52-Week High | $1.49 | $301.27 |
52-Week Low | $0.27 | $106.23 |
Typical Hold Time | 35 Days | 56 Days |
Enterprise Value | $180.78M | $40.34B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.39, up 17.58% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7 million but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics, analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings performance discussions.
The outlook is mixed: strong analyst support and technical momentum suggest potential upside, but persistent losses and high valuation ratios pose significant risks. Investment opportunity hinges on revenue growth translating to profitability, while key risks include execution challenges and competitive pressures in the biotechnology sector.
Twilio (TWLO) trades at $275.77, down 1.65% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 results pending. Revenue growth accelerated to $5.07 billion in 2025, and net income turned positive at $33.83 million, marking a significant improvement from prior losses. Recent inclusion in the S&P 500 index highlights its market recognition and stability.
The outlook remains positive with strong analyst support (76.92% buy ratings) and a consensus price target of $254.65, though current price exceeds this. Key risks include high valuation multiples (P/E 37.71, EV/EBITDA 80.78) and competitive pressures in the customer engagement space. Upside potential hinges on sustained earnings beats and Voice AI adoption, but investors should monitor margin trends and execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Twilio Inc
Twilio Inc. is a cloud-based communication platform-as-a-service company offering communication building blocks that allow for a fully customized customer engagement experience spanning voice, video, chat, and SMS messaging. It does this through various application programming interfaces, or APIs, and prebuilt solution applications aimed at improving customer engagement. The company leverages its Super Network, a global network of carrier relationships, to facilitate high-speed, cost-effective communication.
Read more on TWLO →
